This is particularly true in the treatment of chronic lymphatic leukemia, typified by the approval of the BCL-2 inhibitor venetoclax as a particularly effective rescue therapy for this disease [70]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.